Press Releases Items Per Page 102550 News Category FinancialGeneral Year None20252024202320222021202020192018201720162015201420132012201120102009200820072006 Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma Aug 07, 2012 Nektar to Announce Financial Results for the Second Quarter of 2012 On Thursday, August 9, 2012, After Close of U.S.-Based Financial Markets Aug 02, 2012 Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain Jul 24, 2012 Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017 Jul 10, 2012 Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain Jun 07, 2012 Nektar Therapeutics' President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York May 30, 2012 Nektar Therapeutics Reports Financial Results for the First Quarter of 2012 May 02, 2012 Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets Apr 25, 2012 Nektar to Host Investor and Analyst R&D Day in New York City Apr 10, 2012 Nektar Doses First Subjects in Phase 1 Clinical Study Evaluating NKTR-192, a New Short-Acting Opioid Molecule for the Treatment of Acute Pain Apr 02, 2012 Pagination First page « first Previous page ‹ previous … Page 31 Page 32 Page 33 Page 34 Current page 35 Page 36 Page 37 Page 38 Page 39 … Next page next › Last page last »